Blab Politics
Colombias Congress Passes First Nuclear Law, Establishes Safety Regulator and Opens Path for Medical Isotopes and Future Power Projects
On June 10, 2026, Bogotá’s Congress enacted Colombia’s first comprehensive nuclear law, a milestone that unites lawmakers from both major parties in a rare show of consensus. Dubbed Atoms for Life, the bill creates a National Nuclear Safety Agency that will be the sole regulator of civilian nuclear activities and lays the groundwork for studying nuclear power as a low‑carbon energy source.
For years, oversight of nuclear and radioactive materials in Colombia was scattered across ministries and agencies, leading to confusion and delays. The new agency will issue licenses, conduct inspections, impose penalties, and coordinate with international bodies such as the International Atomic Energy Agency (IAEA). The Ministry of Mines and Energy said the regulator will help the country meet its international safety commitments and uphold its obligations under the Treaty on the Non‑Proliferation of Nuclear Weapons.
While the law does not authorize the construction of a nuclear power plant, it establishes the legal and institutional framework that would be required for any future project. The government has indicated it intends to study nuclear generation around 2035, after drought‑driven shortages in hydroelectric supply and a decline in gas output strain Colombia’s energy mix. The regulator’s existence is a prerequisite for attracting foreign investment and for meeting the conditions set by lenders and technology partners.
The legislation’s most immediate benefit lies in health care. Colombia currently imports most radiopharmaceuticals—radioactive compounds used to diagnose and treat cancer—because the short half‑lives of the isotopes make local production difficult. The new framework will allow the country to develop a domestic supply chain for these materials, potentially reducing shortages and improving access for patients. Colombia already operates a small research reactor in Bogotá, and the law is intended to build on that foundation.
Beyond medical applications, the law signals a broader regional trend. Several Latin American countries are revisiting nuclear power as a hedge against the volatility of hydroelectric and gas resources. Argentina, for example, has decades of reactor experience and exports nuclear technology. Colombia’s move places it on a similar trajectory, though it remains far behind its neighbors.
The unanimous vote across all four congressional debates is notable given the polarized nature of the Colombian legislature. Lawmakers from both major parties agreed that a clear, independent regulator is essential for any future nuclear activity. The consensus suggests that the law has durable political support, although the next step—presidential approval—remains pending.
Once signed, the law will formally establish the National Nuclear Safety Agency, which will be responsible for licensing facilities that use nuclear or radioactive material. The agency will also have the authority to impose penalties and to coordinate with international safety standards. The law’s provisions align with Colombia’s commitments under the Non‑Proliferation Treaty and its obligations to the IAEA.
The immediate effect of the law will be the creation of the regulatory body and the initiation of domestic production of radiopharmaceuticals. The study of nuclear power will remain a long‑term objective, with the first feasibility studies expected in the next few years. The law does not yet set a timeline for the construction of a reactor, but it does provide the legal framework that would be required if the government chooses to pursue that path.
In short, Colombia’s first nuclear law establishes a dedicated safety regulator, aims to improve access to cancer‑treating isotopes, and sets the stage for future nuclear power studies. The law is now awaiting presidential approval, after which the National Nuclear Safety Agency will be formally established and the country will begin the process of licensing and inspecting civilian nuclear facilities.
For years, oversight of nuclear and radioactive materials in Colombia was scattered across ministries and agencies, leading to confusion and delays. The new agency will issue licenses, conduct inspections, impose penalties, and coordinate with international bodies such as the International Atomic Energy Agency (IAEA). The Ministry of Mines and Energy said the regulator will help the country meet its international safety commitments and uphold its obligations under the Treaty on the Non‑Proliferation of Nuclear Weapons.
While the law does not authorize the construction of a nuclear power plant, it establishes the legal and institutional framework that would be required for any future project. The government has indicated it intends to study nuclear generation around 2035, after drought‑driven shortages in hydroelectric supply and a decline in gas output strain Colombia’s energy mix. The regulator’s existence is a prerequisite for attracting foreign investment and for meeting the conditions set by lenders and technology partners.
The legislation’s most immediate benefit lies in health care. Colombia currently imports most radiopharmaceuticals—radioactive compounds used to diagnose and treat cancer—because the short half‑lives of the isotopes make local production difficult. The new framework will allow the country to develop a domestic supply chain for these materials, potentially reducing shortages and improving access for patients. Colombia already operates a small research reactor in Bogotá, and the law is intended to build on that foundation.
Beyond medical applications, the law signals a broader regional trend. Several Latin American countries are revisiting nuclear power as a hedge against the volatility of hydroelectric and gas resources. Argentina, for example, has decades of reactor experience and exports nuclear technology. Colombia’s move places it on a similar trajectory, though it remains far behind its neighbors.
The unanimous vote across all four congressional debates is notable given the polarized nature of the Colombian legislature. Lawmakers from both major parties agreed that a clear, independent regulator is essential for any future nuclear activity. The consensus suggests that the law has durable political support, although the next step—presidential approval—remains pending.
Once signed, the law will formally establish the National Nuclear Safety Agency, which will be responsible for licensing facilities that use nuclear or radioactive material. The agency will also have the authority to impose penalties and to coordinate with international safety standards. The law’s provisions align with Colombia’s commitments under the Non‑Proliferation Treaty and its obligations to the IAEA.
The immediate effect of the law will be the creation of the regulatory body and the initiation of domestic production of radiopharmaceuticals. The study of nuclear power will remain a long‑term objective, with the first feasibility studies expected in the next few years. The law does not yet set a timeline for the construction of a reactor, but it does provide the legal framework that would be required if the government chooses to pursue that path.
In short, Colombia’s first nuclear law establishes a dedicated safety regulator, aims to improve access to cancer‑treating isotopes, and sets the stage for future nuclear power studies. The law is now awaiting presidential approval, after which the National Nuclear Safety Agency will be formally established and the country will begin the process of licensing and inspecting civilian nuclear facilities.
